MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months
The FTC issued a Second Request for more information on MiMedx's (MDXG) acquisition of Sanara (SMTI), delaying the merger beyond the year-end target. SMTI shares fell 5.5%, dropping below their 50-day moving average, while MDXG shares declined 2.8%. The deal, valued at $35 per share, aims to create a larger regenerative medicine company with $400M revenue expected in FY2027.
How this was made
The 30-second read
Why it matters
The FTC issued a Second Request, which extends the mandatory waiting period to 30 days after both companies comply, pushing the timeline beyond the original year-end target and driving a same-day selloff in both merger partners.
Market read
This is a direct, deal-specific antitrust procedural update that changes expected closing timing and increases uncertainty for both counterparties.
What to watch
The article does not quantify compliance progress or any remedies; traders may be over-weighting timeline risk versus deal probability if filings are already underway.
Background
MiMedx agreed in July to acquire Sanara in a cash-and-stock deal at $35 per share, targeting year-end close.
Ticker impact
Sanara MedTech shares fell after the FTC issued a Second Request for the MiMedx-Sanara merger, extending the waiting period by 30 days.
Likely downside bias as traders price a longer timeline and higher deal-risk premium.
The article ties SMTI’s drop to the FTC Second Request and explicitly notes the waiting period extension beyond the original year-end target.
MiMedx Group shares also dropped as the FTC Second Request seeks additional documents for the proposed merger with Sanara, delaying closure.
Likely continued weakness or volatility as the market reprices the probability/timing of completion.
The text links MDXG’s move directly to the FTC Second Request and the resulting 30-day extension after compliance.
Market effects
Adds regulatory overhang risk for regenerative medicine M&A, potentially raising perceived antitrust friction for similar deals.
Limited, primarily affects US-listed merger counterparties and biotech/regenerative-medicine sentiment.
Low, as the catalyst is a US FTC antitrust process for specific companies.
Counterpoint
A Second Request does not imply rejection; if both firms promptly comply, the deal can still close, limiting long-term downside.
Key entities
- companyMiMedx Group
US-listed acquirer in the proposed regenerative medicine merger with Sanara.
- companySanara MedTech
US-listed target in the proposed regenerative medicine merger with MiMedx.
- regulatorFederal Trade Commission (FTC)
Issued a Second Request for additional documents in the antitrust review.
